In VTE at high risk for recurrence, reduced- vs. full-dose DOACs did not differ for symptomatic recurrence but reduced bleeding at 37 mo - KIVIRID

In VTE at high risk for recurrence, reduced- vs. full-dose DOACs did not differ for symptomatic recurrence but reduced bleeding at 37 mo

Authors: Conor Bell, Stephanie Carlin,

Published: 2025-06-02

DOI: 10.7326/annals-25-01856-jc

Source: Full article

Abstract

No abstract found.